The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Setting and Revising Antibacterial Susceptibility Breakpoints
Open accessAbstract
SUMMARY: Clinical microbiology laboratories need to communicate results of antibacterial susceptibility testing to prescribers. Sophisticated prescribers who are knowledgeable of the pharmacokinetics and pharmacodynamics of antibacterials may desire no more information than the MIC of the drug in question. However, most prescribers require interpretation of antibacterial susceptibility testing results. Breakpoints can assist in determining if an antibacterial is potentially useful in the treatment of a bacterial infection. Breakpoints should be set prior to an antibacterial being used clinically. Breakpoint setting requires integration of knowledge of the wild-type distribution of MICs, assessment of the pharmacokinetics/pharmacodynamics of the antibacterial, and study of the clinical outcome of infections when the antibacterial is used. It is mandatory that breakpoints be reviewed when antibacterial agents have been in clinical use for some time, particularly if mechanisms of bacterial resistance to the drug have been described. In general, greater amounts of information on the pharmacokinetics and pharmacodynamics of an antibacterial are available when breakpoints need to be revised. However, the opportunity to conduct randomized clinical studies of an antibacterial declines after the drug has been released commercially. Well-designed observational clinical studies are therefore necessary in order to provide reliable data to inform those reevaluating breakpoints. Breakpoint-setting organizations may also play a role in developing phenotypic tests for detection of resistance mechanisms, as this information may complement use of the breakpoint in some circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Performance standards for antimicrobial susceptibility testing
Ferraro, M. J. (2001) · Cited by 9,667
Determination of minimum inhibitory concentrations
Andrews, J. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.suppl_1.5 · Cited by 4,129
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Self-citation(2006) · PsycEXTRA Dataset · doi:10.1037/e545592006-001 · Cited by 2,958
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Wikler, M. A., & Clinical (2006) · Clinical and Laboratory Standards Institute eBooks · Cited by 2,843
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Fleming, A. (1929) · PubMed Central · Cited by 1,647
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Antibiotic sensitivity testing. Report of an international collaborative study.
Ericsson, H., & Sherris, J. C. (1971) · PubMed · Cited by 1,324
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Self-citationAmbrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Gupta, K., Hooton, T. M., & Stamm, W. E. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-1-200107030-00012 · Cited by 677
[Antibiogram Committee of the French Society for Microbiology. Official Statement 1999].
Soussy, C. (1999) · PubMed · Cited by 677
Rodriguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D. W., Donnelly, J. P., Dromer, F., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01935.x · Cited by 652
Craig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618
Fleming, A. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.1.129 · Cited by 612
Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution
(2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00142.x · Cited by 599
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Self-citationPharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Paterson, D. L., Ko, W.-C., Von Gottberg, A., Casellas, J. M., Mulazimoglu, L., Klugman, K. P., Bonomo, R. A., Rice, L. B., McCormack, J. G., & Yu, V. L. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2206-2212.2001 · Cited by 546
Self-citationSusceptibility testing of antimicrobials in liquid media
Amsterdam, D. (1996) · Medical Entomology and Zoology · Cited by 492
Yu, V. L., Chiou, C. C. C., Feldman, C., Ortqvist, A., Rello, J., Morris, A. J., Baddour, L. M., Luna, C. M., Snydman, D. R., Ip, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/377534 · Cited by 451
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435
(2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00149.x · Cited by 410
Development of in vitro susceptibility testing criteria and quality control parameters
Novick, W. J. (1989) · Clinical Microbiology Newsletter · doi:10.1016/0196-4399(89)90068-8 · Cited by 407
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397
Self-citationEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397
Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Role of pharmacokinetics in the outcome of infections
Drusano, G. L. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.3.289 · Cited by 330
Killing and regrowth of bacteria in vitro: a review.
Craig, W. A., & Ebert, S. C. (1990) · PubMed · Cited by 303
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
Pharmacokinetics and Pharmacodynamics of Fluoroquinolones
Turnidge, J. (1999) · Drugs · doi:10.2165/00003495-199958002-00006 · Cited by 289
Self-citationIn Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4574-4581.2004 · Cited by 267
Pharmacodynamics of cefepime in patients with Gram-negative infections
Tam, V. H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf130 · Cited by 262
In Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic Mice
Vogelman, B., Gudmundsson, S., Turnidge, J., Leggett, J., & Craig, W. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.2.287 · Cited by 259
Self-citationDrusano, G. L., Preston, S. L., Fowler, C., Corrado, M., Weisinger, B., & Kahn, J. (2004) · The Journal of Infectious Diseases · doi:10.1086/383320 · Cited by 245
Drusano, G. L., Preston, S. L., Hardalo, C., Hare, R., Banfield, C., Andes, D., Vesga, O., & Craig, W. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.13-22.2001 · Cited by 243
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
Oxford, J. S., Bossuyt, S., Balasingam, S., Mann, A., Novelli, P., & Lambkin, R. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00564.x · Cited by 233
Eagle, H., Fleischman, R., & Levy, M. (1953) · New England Journal of Medicine · doi:10.1056/nejm195303192481201 · Cited by 230
Franklin, C., Liolios, L., & Peleg, A. Y. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00879-06 · Cited by 227
Raz, R., Chazan, B., Kennes, Y., Colodner, R., Rottensterich, E., Dan, M., Lavi, I., Stamm, W., & the Israeli Urinary Tract Infection Group (2002) · Clinical Infectious Diseases · doi:10.1086/339812 · Cited by 221
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J., Williams, R. R., Fowler, C. L., Cheung, W. K., & Chow, A. T. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2256 · Cited by 217
Crump, J. A., Barrett, T. J., Nelson, J. T., & Angulo, F. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375602 · Cited by 216
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Susceptibility Tests of Anaerobic Bacteria: Statistical and Clinical Considerations
Metzler, C. M., & DeHaan, R. M. (1974) · Journal of Infectious Diseases · doi:10.1093/infdis/130.6.588 · Cited by 196
McDonald, P. J., Wetherall, B. L., & Pruul, H. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.38 · Cited by 187
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests
MacGowan, A. P., & Wise, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.suppl_1.17 · Cited by 187
Blower, S., Bodine, E., Kahn, J., & McFarland, W. (2005) · AIDS · doi:10.1097/00002030-200501030-00001 · Cited by 161
Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis
Zelenitsky, S. A., Harding, G. K. M., Sun, S., Ubhi, K., & Ariano, R. E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg403 · Cited by 156
Brown, P. D., Freeman, A., & Foxman, B. (2002) · Clinical Infectious Diseases · doi:10.1086/339491 · Cited by 132
Andes, D. R., & Craig, W. A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01265.x · Cited by 130
Forrest, A., Chodosh, S., Amantea, M., et al. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.suppl_1.45 · Cited by 130
Role for Dual Individualization with Cefmenoxime
Schentag, J. J., Smith, I. L., Swanson, D. J., DeAngelis, C., Fracasso, J. E., Vari, A., & Vance, J. W. (1984) · The American Journal of Medicine · doi:10.1016/s0002-9343(84)80074-1 · Cited by 129
Knudsen, J. D., Fuursted, K., Raber, S. R., Espersen, F., & Frimodt‐Møller, N. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1247-1254.2000 · Cited by 115
Antimicrobial resistance issues of the future
Craig, W. A. (1996) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(96)00162-9 · Cited by 114
Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function
Tam, V. H., McKinnon, P. S., Akins, R. L., Drusano, G. L., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1853-1861.2003 · Cited by 111
Dudley, M. N., & Ambrose, P. G. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00132-6 · Cited by 109
Selection of Aminoglycoside-Resistant Variants of Pseudomonas aeruginosa in an in Vivo Model
Gerber, A., Vastola, A. P., Brandel, J., et al. (1982) · The Journal of Infectious Diseases · doi:10.1093/infdis/146.5.691 · Cited by 108
The CDS Disc Method of Antibiotic Sensitivity Testing (Calibrated Dichotomous Sensitivity Test)
Bell, S. M., & Smith, D. D. (1975) · Pathology · doi:10.3109/00313027509082602 · Cited by 97
In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media
Géhanno, P., Lenoir, G., & Berche, P. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.271 · Cited by 91
Treatment of Uncomplicated Urinary Tract Infections in an Era of Increasing Antimicrobial Resistance
Miller, L. G., & Tang, A. W. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.8.1048 · Cited by 84
Kronvall, G., Kahlmeter, G., Myhre, E. B., & Galas, M. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00546.x · Cited by 82
Szabó, D., Bonomo, R. A., Silveira, F. P., Pasculle, A. W., Baxter, C. M., Linden, P. K., Hujer, A. M., Hujer, K. M., Deeley, K. B., & Paterson, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5058-5064.2005 · Cited by 66
Self-citationRole of Angiotensin Converting Enzyme Inhibitors in Essential and Renal Hypertension
Bauer, J. H. (1984) · The American Journal of Medicine · doi:10.1016/s0002-9343(84)80057-1 · Cited by 63
Davies, T. A., Evangelista, A. T., Pfleger, S., Bush, K., Sahm, D. F., & Goldschmidt, R. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.119-124.2002 · Cited by 63
Special Phenotypic Methods for Detecting Antibacterial Resistance
Limbago, B. M., & Swenson, J. M. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch73 · Cited by 57
Snydman, D. R., Cuchural, G. J., McDermott, L. A., & Gill, M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.3.540 · Cited by 55
Impact of pharmacodynamics on breakpoint selection for susceptibility testing
Mouton, J. W. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00062-x · Cited by 51
Wart, S. V., Phillips, L., Ludwig, E. A., Russo, R., Gajjar, D. A., Bello, A., Ambrose, P. G., Costanzo, C., Grasela, T. H., ECHOLS, R. M., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4766-4777.2004 · Cited by 48
Determination of antimicrobial susceptibility test breakpoints
(2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00178.x · Cited by 45
Management of pneumococcal meningitis
Kaplan, S. L. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200206000-00034 · Cited by 44
Turnidge, J., & Bordash, G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01457-06 · Cited by 44
Self-citationFalcó, V., Almirante, B., Jordano, Q., Calonge, L., del Valle, O., Pigrau, C., Planes, A. M., Gavaldà, J., & Pahissa, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh338 · Cited by 44
Kronvall, G., Karlsson, I., Walder, M., Sörberg, M., & Nilsson, L. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki489 · Cited by 43
Koeth, L. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.369 · Cited by 40
Modeling approach to diameter breakpoint determination
Craig, B. Α. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00130-3 · Cited by 39
Kellner, J. D., Scheifele, D. W., Halperin, S. A., LEBEL, M. H., MOORE, D. L., Saux, N. M. L., Ford-Jones, E. L., LAW, B. J., & Vaudry, W. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200210000-00004 · Cited by 37
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Self-citationExtensive impact of non-antibiotic drugs on human gut bacteria
Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., et al. (2018) · Nature · doi:10.1038/nature25979 · Cited by 1,905
“In 68% of cases, IC 25 s are equal between replicates and in further 22%, there is a two-fold change between replicates, which is within the two-fold error margin reported for inhibitory concentration 58.”
Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A., & Parry, C. M. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00002-15 · Cited by 1,156
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Stemming the Superbug Tide: Just A Few Dollars More
OECD (2018) · OECD Health Policy Studies · doi:10.1787/9789264307599-en · Cited by 748
Metadata
- Authors
- Turnidge, J., & Paterson, D. L.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2007-07
- Volume
- 20
- Issue
- 3
- Pages
- 391-408
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2132112261
- Cited by
- 578
- References
- 88
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.